The EMAS 2006/2007 update on clinical recommendations on postmenopausal hormone therapy.
This new statement from EMAS presents the findings reported in recent publications from both WHI trials. In general, the reports do not necessitate a revision of the current EMAS advice. They provide further insight into the ongoing controversy around the possibility that hormone therapy (HT) in the form of estrogen (E) alone or estrogen-progestogen (EP) may influence risk of breast cancer differently. They confirm that the increase of breast cancer diagnosis under EP is only significant after a cumulative use of more than 5 years but suggest that there is no increased risk by E within 10 years.
Gompel
Anne
A
Frederiksberg Hospital, Department of Ob/Gyn, 2000 Copenhagen F, Denmark.
Barlow
David
D
Rozenberg
Serge
S
Skouby
Sven O
SO
D015914:Estrogen Replacement Therapy / Q000009:adverse effects / Q000379:methods*; D004966:Estrogens, Conjugated (USP) / Q000009:adverse effects; D005060:Europe; D005260:Female; D006801:Humans; D017410:Practice Guidelines as Topic; D012955:Societies, Medical; D016387:Women's Health
D004966:Estrogens, Conjugated (USP)